Determinants of Human Papillomavirus Vaccine recommendation among Middle Eastern and Lebanese Healthcare Providers

dc.contributor.authorJaafar, Iman
dc.contributor.authorAtallah, David M.
dc.contributor.authorMirza, Fadi Ghazi
dc.contributor.authorAbu-Musa, Antoine A.
dc.contributor.authorEl-Kak, Faysal H.
dc.contributor.authorSeoud, Muhieddine A.F.
dc.contributor.departmentObstetrics and Gynecology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:12Z
dc.date.available2025-01-24T12:08:12Z
dc.date.issued2022
dc.description.abstractObjective: To improve the knowledge, awareness, and attitude (KAA) among health care providers (HCPs) regarding Human Papilloma Virus vaccination (HPV-V), the Lebanese Society of Obstetrics and Gynecology (LSOG) has regularly organized educational meetings, symposia, and workshops. Methods: We conducted two sets of surveys among attendees of the LSOG congresses in 2009 and 2018 to assess their KAA towards HPV-V. Results: Around 30% (362) of LSOG attendees participated in our surveys in 2009 and 2018 (185 Vs.177 respectively). Most of them were obstetricians and gynecologists. Most HCPs considered that HPV-V can prevent cervical cancer (CC) [82% and 80% respectively, P = 0.73], however, around 60% were confident enough to convince their patients. HCPs who were confident about the efficacy of the HPV-Vs were more likely to believe that HPV-V can prevent CC (odds ratio = 22.5, p-value = 0.003). These HCPS were more likely to recommend HPV-V (OR = 6.6, p-value = 0.009). About 20% of HCPs who usually recommend HPV-V, reported cost as a main barrier compared to 76% of those who did not. Conclusions: Being familiar with HPV, HPV-related diseases, CC, HPV vaccines and their effectiveness significantly influence whether a HCP recommends HPV-V. The KAA of HCPs did not significantly improve from 2009 to 2018. © 2022 The Author(s)
dc.identifier.doihttps://doi.org/10.1016/j.cegh.2022.101092
dc.identifier.eid2-s2.0-85136568993
dc.identifier.urihttp://hdl.handle.net/10938/31754
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofClinical Epidemiology and Global Health
dc.sourceScopus
dc.subjectAttitude
dc.subjectHealth personnel
dc.subjectKnowledge
dc.subjectLebanon
dc.subjectPapillomavirus vaccines
dc.subjectHuman papilloma virus vaccine
dc.subjectAdult
dc.subjectAged
dc.subjectArticle
dc.subjectChild
dc.subjectClinical article
dc.subjectComparative study
dc.subjectFemale
dc.subjectGeneral practitioner
dc.subjectGynecologist
dc.subjectHealth care cost
dc.subjectHealth care personnel
dc.subjectHuman
dc.subjectLebanese
dc.subjectMale
dc.subjectMiddle aged
dc.subjectObstetrician
dc.subjectPapillomavirus infection
dc.subjectPediatrician
dc.subjectSerotype
dc.subjectUterine cervix cancer
dc.subjectVaccination
dc.titleDeterminants of Human Papillomavirus Vaccine recommendation among Middle Eastern and Lebanese Healthcare Providers
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1518.pdf
Size:
400.29 KB
Format:
Adobe Portable Document Format